MRC1 and neoplasm: As expected, the group receiving aPD-1@NP displayed a slightly increased proportion of M1 TAMs (CD80 as marker) and CD8+ T cells and a mildly reduced proportion of M2 TAMs (CD206 as marker), Tregs and MDSCs in the tumor tissues (Fig. 5C).